{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-067071","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.348586+00:00","generated_at":"2026-05-24T03:19:50.643254+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenaya Therapeutics approves restructuring; workforce reduction extends cash runway to H2 2026","bullets":["Restructuring focuses resources on TN-201 (MyPEAK-1) and TN-401 (RIDGE-1) gene therapy trials.","Workforce reduction implemented; no expected impact on enrollment milestones or data readouts.","Estimated severance and health benefit charges of $1.6M–$2.7M, substantially all by Q3 2025.","Cash runway extended into second half of 2026 via cost-containment measures.","Sufficient drug product produced for ongoing trials; manufacturing for pivotal studies continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-067071","json":"https://secwatch.observer/filing/0001193125-25-067071.json","markdown":"https://secwatch.observer/filing/0001193125-25-067071.md","text":"https://secwatch.observer/filing/0001193125-25-067071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/0001193125-25-067071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/d660778d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:19:50.643254+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}